{
    "content": "Diagnosis:\tAdvanced colon cancer with synchronous liver metastases, T4N2M1 (AJCC Stage IV), moderately differentiated adenocarcinoma, KRAS wild type, BRAF negative, MMR-proficient.\n\nTreatment:\t20.03.2021: Right hemicolectomy and liver resection (2 segments) - macroscopic complete resection, 3/23 lymph nodes positive.\n\t\t12 cycles adjuvant FOLFOX completed 01.2022 - mild neuropathy noted.\n\t\t07.2022: Disease progression with new hepatic lesions.\n\t\t07.2022-02.2023: 6 cycles FOLFIRI + bevacizumab, ceased due to grade 3 diarrhea and progression.\n\t\t03.2023: Transarterial chemoembolization (TACE) for hepatic metastases - partial response.\n\t\t06.2023-10.2023: Capecitabine monotherapy - mixed response with stable hepatic lesions but new peritoneal deposits.\n\t\t11.2023: Palliative RT to symptomatic pelvic mass 20Gy/5#.\n\t\t01.2024-12.2024: Encorafenib + cetuximab - partial response, continued fatigue, and worsening neuropathy.\n\nCurrent Situation:\tCompleted last cycle of encorafenib + cetuximab in December 2024.\n\nSymptoms:\tGrade 2 neuropathy in hands and feet, fatigue, mild intermittent abdominal pain.\n\nExamination:\tReduced grip strength bilaterally, mild peripheral edema, stable weight.\n\nInvestigations:\tCT 15.12.2024 shows 50% reduction in liver lesions and stable peritoneal disease.\n\nPlan:\tTransition to surveillance protocol with 3-monthly CT and tumor markers.\n\tContinue physiotherapy for neuropathy and fatigue management.\n\tFollow-up with GI oncology clinic in 4 weeks to reassess symptoms and imaging.\n\tLetter copied to GP and palliative care team for ongoing support.",
    "output": {
      "primary_cancer": {
        "site": "colon",
        "year": 2021,
        "month": 3,
        "metastases": "liver and peritoneal metastases",
        "tnm_stage": "T4N2M1",
        "other_stage": "AJCC Stage IV",
        "histopathology_status": "moderately differentiated adenocarcinoma",
        "biomarker_status": "KRAS wild type, BRAF negative, MMR-proficient",
        "cancer_timeline": [
          {
            "type": "treatment_surgery",
            "value": "Right hemicolectomy and liver resection (2 segments)",
            "year": 2021,
            "month": 3
          },
          {
            "type": "treatment_systemic_start",
            "value": "12 cycles adjuvant FOLFOX",
            "year": 2021,
            "month": 4
          },
          {
            "type": "treatment_systemic_change",
            "value": "Ceased FOLFOX, completed 12 cycles",
            "year": 2022,
            "month": 1
          },
          {
            "type": "other_progress_or_event",
            "value": "Disease progression with new hepatic lesions",
            "year": 2022,
            "month": 7
          },
          {
            "type": "treatment_systemic_start",
            "value": "6 cycles FOLFIRI + bevacizumab",
            "year": 2022,
            "month": 7
          },
          {
            "type": "treatment_systemic_change",
            "value": "Ceased FOLFIRI + bevacizumab due to grade 3 diarrhea and progression",
            "year": 2023,
            "month": 2
          },
          {
            "type": "treatment_radiotherapy",
            "value": "Palliative RT to symptomatic pelvic mass 20Gy/5#",
            "year": 2023,
            "month": 11
          },
          {
            "type": "treatment_systemic_start",
            "value": "Encorafenib + cetuximab",
            "year": 2024,
            "month": 1
          },
          {
            "type": "treatment_systemic_change",
            "value": "Completed encorafenib + cetuximab",
            "year": 2024,
            "month": 12
          },
          {
            "type": "investigation_finding",
            "value": "CT shows 50% reduction in liver lesions and stable peritoneal disease",
            "year": 2024,
            "month": 12
          }
        ]
      },
      "patient_facts": [
        {
          "type": "current_symptom",
          "value": "Grade 2 neuropathy in hands and feet"
        },
        {
          "type": "current_symptom",
          "value": "fatigue"
        },
        {
          "type": "current_symptom",
          "value": "mild intermittent abdominal pain"
        },
        {
          "type": "examination_finding",
          "value": "Reduced grip strength bilaterally"
        },
        {
          "type": "examination_finding",
          "value": "mild peripheral edema"
        }
      ],
      "status_updates": [
        {
          "type": "clinical_summary",
          "value": "Stage IV colon cancer with liver and peritoneal metastases achieving partial response after multiple lines of therapy, transitioning to surveillance after completing encorafenib + cetuximab."
        },
        {
          "type": "update_to_treatment",
          "value": "Transition to surveillance protocol with 3-monthly CT and tumor markers"
        },
        {
          "type": "planned_investigation",
          "value": "Follow-up CT and tumor markers in 3 months"
        },
        {
          "type": "follow_up_referral",
          "value": "Follow-up with GI oncology clinic in 4 weeks"
        }
      ]
    }
  }
  